Skip to main content

Table 1 Baseline characteristics of patients with anti-HMGCR myopathy (N = 55)

From: Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients

 n (%) or median (range)
Sex, male/female30/25
Age at diagnosis, median (range), years67.7 (44–86.1)
Prior statin use, n (%)55 (100)
 Atorvastatin use, n (%)46 (84)
Diabetes mellitus, n (%)39 (72)
Cardiovascular disease, n (%)*29 (53)
Cancer within 3 years of diagnosis, n0
First serum CK levels at presentation, median (range), UI/L2935 (500–19,465)
CK levels at treatment initiation, median (range), UI/L5000 (554–23,000)
Myalgias, n (%)21 (38)
Subjective oropharyngeal dysphagia, n (%)16 (29)
Objective oropharyngeal dysphagia, n (%)5 (9)
Proximal muscle weakness at presentation, n (%)33 (60)
Proximal muscle weakness at treatment initiation, n (%)46 (84)
Muscle biopsy, n (%)54 (98)
 Necrosis and regeneration, n (%)48 (87)
 Isolated sarcolemmal/capillary MAC deposition, n (%)4 (7)
 Regeneration only, n (%)1 (2)
 Normal, n (%)1 (1)
 Other abnormalities
  MHC-1 expression on non-necrotic muscle fibers, n (%)26/51 (51)
  Sarcolemmal and/or capillary MAC deposition, n (%)**38/42 (90)
  1. *Myocardial infarction or stroke
  2. **MAC deposition was found on non-necrotic fibers and/or endomysial capillaries